Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Radiopharm Theranostics Limited ( (AU:RAD) ) just unveiled an announcement.
Radiopharm Theranostics Limited has announced the proposed issuance of 39,644,767 fully paid ordinary shares through a placement expected to occur on December 31, 2027. This move demonstrates the company’s commitment to further strengthening its capital base, potentially facilitating expansion, innovation in radiopharmaceutical development, and improved positioning within the industry as it continues to pursue technological advancement in cancer treatment and diagnostics.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the medical and biotechnology industry, focusing on developing and delivering radiopharmaceutical drugs and diagnostics for cancer treatment and imaging. The company aims to use innovative technology to advance oncological care, targeting markets that benefit from precision medicine.
Average Trading Volume: 11,532,554
Technical Sentiment Signal: Buy
Current Market Cap: A$102.8M
See more insights into RAD stock on TipRanks’ Stock Analysis page.